Merck Serono

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Merck Serono
EMD Serono
Type Stock corporation
Founded 1668
Location Darmstadt, Germany (Headquarters)
Key people
Industry Biotechnology / Pharmaceutical
Key Products Rebif, Mavenclad, Gonal-f, Luveris, Ovidrel/Ovitrelle, Serostim, Saizen, Zorbtive, Erbitux and Bavencio
Revenue USD ~5 billion (projected)
The former headquarters of Merck Serono in Geneva (which now hosts the Campus Biotech).

Merck Serono (EMD Serono in the United States and Canada) is a pharmaceutical company headquartered in Darmstadt, Germany, and a brand and division of Merck focused on biopharmaceuticals.[1]

In September 2006, Merck KGaA announced its intent to purchase the majority of Serono shares from Ernesto Bertarelli and the Bertarelli family. The Merck-Serono merger was announced on 21 September 2006. Merck KGaA and Serono operated as distinct entities until at least January 2007. As of January 5, 2007, Merck held the majority shares of Serono. The new company is called Merck Serono international SA. In 2012, Merck Serono moved its headquarters from Geneva, Switzerland to Darmstadt.

Drugs they market include Erbitux, UFT, Rebif, Mavenclad, Novantrone, Gonal, Ovidrel/Ovitrelle, Zorbtive, Luveris, Saizen, Serostim, Glucophage, Concor and Euthyrox. Raptiva was withdrawn in 2007.

In the U.S. and Canada, Merck Serono is known as EMD Serono, as the former Merck subsidiary Merck & Co. holds the rights to the name Merck in those countries.

Collaborative research[edit]

In addition to internal research and development activities Merck Serono with the help of Toledana, is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[2][3] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[4]

Notes and references[edit]

  1. ^ Background Info,
  2. ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
  3. ^ "InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 2008-08-25.
  4. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 15 October 2009. Retrieved 25 August 2008.

See also[edit]

External links[edit]